Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial

This 2021 randomized controlled trial evaluated the long-term safety and efficacy of umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy in patients with hepatitis B virus (HBV)-related decompensated liver cirrhosis (DLC). A total of 250 patients were randomized to receive either standard care or standard care plus UC-MSC infusions at weeks